Activity of ciprofloxacin against resistant clinical isolates
- 1 March 1986
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 17 (3), 281-286
- https://doi.org/10.1093/jac/17.3.281
Abstract
The in-vitro activity of ciprofloxacin, a new quinolone derivative, was determined by broth microdilution for 518 clinical isolates. The MICs for 90% of the organisms were 2 mg/1 for Pseudomonas aeruginosa, 8 mg/l for P. maltophilia, 4 mg/1 for other Pseudomonas spp., 1 mg/1 for Acinetobacter anitratus, 0.03–0.5 mg/l for differing species of Enterobacteriaceae, 2 mg/l for Streptococcus faecalis, 0.25 mg/l for coagulase-negative Staphylococcus spp. and 2 mg/l for S. aureus. Furthermore, on a weight basis, the activity of ciprofloxacin was equivalent or superior to that of cefotaxime, ceftazidime, gentamicin, imipenem, latamoxef, piperacillin, oxacillin and vancomycin. In general, ciprofloxacin appears to be highly active against organisms resistant to many broad spectrum antimicrobials, including norfloxacin, gentamicin, cefotaxime, and ceftazidime, with MICs for 90% of organisms in the range of 0.03 to 16 mg/l.Keywords
This publication has 4 references indexed in Scilit:
- In vitro activity of ciprofloxacin (Bay o 9867)Antimicrobial Agents and Chemotherapy, 1983
- In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1983
- In vitro and in vivo activity of DL-8280, a new oxazine derivativeAntimicrobial Agents and Chemotherapy, 1982
- In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprimAntimicrobial Agents and Chemotherapy, 1982